Sio Gene up on successful manufacturing of Parkinson's disease therapy

Sio Gene Therapies

11/11/2021 13:27

** Shares of drug developer  SIOX.O  up ~5% at $2.03
premarket
    ** Co says it has successfully manufactured three batches of
AXO-Lenti-PD, its investigational gene therapy for Parkinson's
disease  urn:newsml:reuters.com:*:nGNX7TRKt9
    ** "We now have a process that has generated sufficient
clinical trial material for future clinical development", said
Pavan Cheruvu, CEO of SIOX
    ** Co on track to complete final testing of these three
batches to support certification of at least one batch for use
as clinical trial material before the end of the year
    ** SIOX also successfully completed meeting with MHRA in UK
regarding further development of AXO-Lenti-PD
    ** All 5 brokerages covering stock rate it "buy" or higher;
their median PT is $8
    ** Up to Wednesday's close, stock had fallen 30.58% YTD
    
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))